Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole von Umehara, Hiroshi, Maekawa, Yoshimi, Koizumi, Fumito, Shimizu, Makiko, Ota, Toshio, Fouad, Tamer M., Willey, Jie, Kaito, Hidekuni, Shiraishi, Norihiko, Nakashima, Daisuke, Akinaga, Shiro, Ueno, Naoto T.

Volltext

Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants von Boyce, Malcolm, Wilkes, Denisa, Kaito, Hidekuni, Takanuma, Masayuki, Arai, Yasumasa

Volltext

A randomized, double-blind, single dose comparison of pharmacokinetics and safety of FKB238 with bevacizumab von Kaito, Hidekuni, van den Berg, Frans, Niewiarowski, Andrew, Boyce, Malcolm

Volltext

Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer von Sarantopoulos, John, Mita, Monica M., Birrer, Michael J., Cranmer, Lee D., Campos, Luis T., Zhang, Xiaoping, Bristow, Penelope, Kaito, Hidekuni, Strout, Vincent, Camacho, Luis H.

Volltext